VRSK

Verisk is a high-quality data, analytics, and workflow software provider embedded in P&C insurance, where proprietary datasets, regulatory/industry standards, and switching costs create a durable moat and strong pricing power. Its product cadence is increasingly AI-led (e.g., GenAI underwriting assistant and XactAI for claims), which should deepen customer stickiness by reducing cycle times and improving loss performance. The key industry trend is insurers’ push to automate underwriting/claims while managing catastrophe volatility, which supports ongoing demand for Verisk’s decision-support tools.

Financially, recent results point to resilient fundamentals: Q4 2025 adjusted EPS was $1.82 (beat) and adjusted EBITDA margin was about 56.1%, with Q4 revenue about $779M (+~6% YoY) and strong free cash flow (~$276M in Q4). Market cap is roughly $28B as of March 2026, and the stock screens at about 29x earnings, which is not cheap but can be justified by a subscription-heavy mix (roughly 83–84% of revenue) and steady mid-single-digit organic growth. A notable uncertainty is M&A execution: Verisk terminated the $2.35B AccuLynx deal after FTC delays and is redeeming acquisition-related debt, reducing near-term integration upside but also limiting balance-sheet risk.

Over the next 12 months, the thesis is that Verisk can compound earnings through AI-enabled product upgrades, continued subscription growth, and operating leverage in a high-margin model. Catalysts include accelerating AI product adoption in commercial underwriting and claims, plus better weather/cat activity normalization versus a low-activity 2025 that management cited as a temporary growth headwind. Key risks are valuation sensitivity (multiple compression if growth slows) and any customer pushback on pricing amid insurer cost cutting.

Recommendation: HOLD. The business quality and cash-generation are strong, but the stock’s ~29x P/E leaves less margin of safety while post-AccuLynx strategy and growth durability need another couple of quarters to re-prove the upside.